Gateway Investment Advisers LLC Purchases 1,222 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Gateway Investment Advisers LLC boosted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 19.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,383 shares of the biopharmaceutical company's stock after buying an additional 1,222 shares during the period. Gateway Investment Advisers LLC's holdings in Alnylam Pharmaceuticals were worth $1,737,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Huntington National Bank boosted its stake in Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 45 shares in the last quarter. Hollencrest Capital Management bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $29,000. Washington Trust Advisors Inc. purchased a new position in Alnylam Pharmaceuticals in the 3rd quarter worth $42,000. True Wealth Design LLC lifted its stake in Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 153 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd purchased a new stake in Alnylam Pharmaceuticals during the third quarter valued at about $45,000. Institutional investors own 92.97% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on ALNY shares. Sanford C. Bernstein lowered their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating for the company in a research note on Tuesday, January 7th. HC Wainwright reissued a "buy" rating and set a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, January 13th. Wolfe Research downgraded shares of Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a research note on Tuesday, November 12th. Needham & Company LLC reissued a "buy" rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, January 13th. Finally, William Blair restated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $298.61.

Alnylam Pharmaceuticals Stock Down 1.2 %

ALNY stock traded down $2.89 on Friday, reaching $246.27. 556,461 shares of the company traded hands, compared to its average volume of 504,065. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The company has a market cap of $31.76 billion, a P/E ratio of -94.00 and a beta of 0.34. The firm has a fifty day simple moving average of $246.62 and a 200-day simple moving average of $259.70. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. Alnylam Pharmaceuticals's quarterly revenue was down 33.3% compared to the same quarter last year. During the same quarter last year, the firm posted $1.15 EPS. Research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,469 shares of the company's stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the transaction, the executive vice president now owns 13,191 shares in the company, valued at approximately $3,310,677.18. This represents a 10.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CMO Pushkal Garg sold 1,682 shares of the firm's stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the sale, the chief marketing officer now directly owns 17,457 shares in the company, valued at approximately $4,381,357.86. The trade was a 8.79 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,122 shares of company stock valued at $2,540,455. 1.50% of the stock is owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.